ArticleeLife2024
An antimicrobial drug recommender system using MALDI-TOF MS and dual-branch neural networks.
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of machine learning on clinical MALDI-TOF MS.Briefings in bioinformatics · 2026Pooled it
- Recent advancements in artificial intelligence applications for the mitigation of antimicrobial resistance: challenges and opportunities.JAC-antimicrobial resistance · 2026Review
- Rapid identification of carbapenem-resistant Acinetobacter baumannii based on MALDI-TOF mass spectrometry and machine learning.BMC microbiology · 2026Article
- Benchmarking deep learning architectures for MALDI-TOF mass spectrometry in infectious disease diagnostics and vector-borne disease surveillance.NPJ digital medicine · 2026Article
- Early antifungal resistance prediction based on MALDI-TOF mass spectrometry and machine learning.Scientific reports · 2026Article
- [Advances in the Application of Artificial Intelligence in Clinical Microbiological Testing].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Review
- Generalizable machine learning models for rapid antimicrobial resistance prediction in unseen health care settings.GigaScience · 2026Article
- Spectral Precision: Recent Advances in Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for Pathogen Detection and Resistance Profiling.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Timely and effective use of antimicrobial drugs can improve patient outcomes, as well as help safeguard against resistance development. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is currently routinely used in clinical diagnostics for rapid species identification. Mining additional data from said spectra in the form of antimicrobial resistance (AMR) profiles is, therefore, highly promising. Such AMR profiles could serve as a drop-in solution for drastically improving treatment efficiency, effectiveness, and costs. This study endeavors to develop the first machine learning models capable of predicting AMR profiles for the whole repertoire of species and drugs encountered in clinical microbiology. The resulting models can be interpreted as drug recommender systems for infectious diseases. We find that our dual-branch method delivers considerably higher performance compared to previous approaches. In addition, experiments show that the models can be efficiently fine-tuned to data from other clinical laboratories. MALDI-TOF-based AMR recommender systems can, hence, greatly extend the value of MALDI-TOF MS for clinical diagnostics. All code supporting this study is distributed on PyPI and is packaged at https://github.com/gdewael/maldi-nn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.